Chimeric Antigen Receptor Therapy: How Are We Driving in Solid Tumors?
Over the past few years, adoptive cell therapy, also known as immune effector cell (IEC) therapy (Maus and Nikiforow, 2017), has emerged as a leading technology, providing precise, immune-mediated antigen directed therapy against cancer. Broadly, cellular immunotherapy strategies include tumor infiltrating lymphocytes (TIL), activated tumor and viral specific T cells, and genetically modified T cell receptor (TCR) or chimeric antigen receptor (CAR) T cells. CAR T cells are an effective, directed therapy, recently translated from the research phase of development to commercially available products for hematological malignancies.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Uri Greenbaum, Fevzi F. Yalniz, Samer A. Srour, Katayoun Rezvani, Harjeet Singh, Amanda Olson, George Blumenschein, David S. Hong, Elizabeth J. Shpall, Partow Kebriaei Source Type: research
More News: Biology | Cancer | Cancer & Oncology | Genetics | Hematology | Immunotherapy | Transplants